Revenues for the 1st quarter of 2012 up +96.5%

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its revenues for the 1st quarter to 31 March.

- Change in quarterly revenues*

<table>
<thead>
<tr>
<th>€ thousands</th>
<th>Q1 2012</th>
<th>Q1 2011</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>494.0</td>
<td>251.4</td>
<td>+96.5%</td>
</tr>
</tbody>
</table>

* Unaudited

Revenues totaled €494.0 thousand over the 1st quarter of 2012, compared to €251.4 thousand over the first quarter of 2011, an increase of +96.5%. This increase in activity reflects the growing routine use of STENTYS stents in hospitals of the 8 European countries in which they are in premarketing phase.

As a reminder, the Company announced in the 1st quarter of 2012 that the reimbursement of self-expanding stents in Germany has been extended to all indications and that STENTYS’ technology has been strongly supported by the conclusions of an American study by world-renowned pathologist Dr. Renu Virmani. On the financial side, STENTYS increased its cash position with a fund raising of €8.3 million in January; STENTYS’ cash position at 31 December 2011 was €14.7 million.

Several announcements expected during the upcoming EuroPCR congress

As previously announced, 2012 will be a year of many developments for STENTYS. The 30-day results of the APPPOSITION III international trial on 1,000 patients will be presented at the EuroPCR congress that will be held from 15 to 18 May in Paris. The 12-month interim results are expected by the end of the year. Furthermore, the Company also expects to get FDA (Food and Drug Administration) approval to launch the APPPOSITION V clinical trial in the United States.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: “We are confident that we will continue to record sales growth in 2012, a year that should notably be marked by FDA approval to launch our clinical trials in the United States.”

- Next press release
Revenues for the 1st half of 2012 will be published on 25 July 2012, after market.

About STENTYS:
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

For further information, go to: www.stentys.com

Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor & Press Relations
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT